Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.

Roma C, Rachiglio AM, Pasquale R, Fenizia F, Iannaccone A, Tatangelo F, Antinolfi G, Parrella P, Graziano P, Sabatino L, Colantuoni V, Botti G, Maiello E, Normanno N.

Cancer Biol Ther. 2016 Aug 2;17(8):840-8. doi: 10.1080/15384047.2016.1195048.

2.

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.

Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J.

Int J Cancer. 2011 May 1;128(9):2075-84. doi: 10.1002/ijc.25555.

3.

A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.

Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T, Gibbs P, Sieber O, Waring P, Desai J.

Target Oncol. 2015 Mar;10(1):99-109. doi: 10.1007/s11523-014-0319-8. Epub 2014 May 27.

4.

Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.

Nakaji Y, Oki E, Nakanishi R, Ando K, Sugiyama M, Nakashima Y, Yamashita N, Saeki H, Oda Y, Maehara Y.

J Cancer Res Clin Oncol. 2017 Jan;143(1):151-160. doi: 10.1007/s00432-016-2275-4. Epub 2016 Sep 26.

PMID:
27672042
5.

High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles.

Chen D, Huang JF, Xia H, Duan GJ, Chuai ZR, Yang Z, Fu WL, Huang Q.

Anal Bioanal Chem. 2014 Apr;406(9-10):2477-87. doi: 10.1007/s00216-014-7618-x. Epub 2014 Feb 6.

PMID:
24500755
6.

Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JD, Vnencak-Jones CL.

Clin Colorectal Cancer. 2013 Sep;12(3):168-78. doi: 10.1016/j.clcc.2013.04.005. Epub 2013 Jun 14.

7.

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.

Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F.

Ann Oncol. 2015 Oct;26(10):2092-7. doi: 10.1093/annonc/mdv290. Epub 2015 Jul 7.

8.

Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.

Zlobec I, Kovac M, Erzberger P, Molinari F, Bihl MP, Rufle A, Foerster A, Frattini M, Terracciano L, Heinimann K, Lugli A.

Int J Cancer. 2010 Dec 1;127(11):2569-75. doi: 10.1002/ijc.25265.

9.

KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.

Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY.

World J Gastroenterol. 2015 Feb 7;21(5):1595-605. doi: 10.3748/wjg.v21.i5.1595.

10.

Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.

Rössle M, Sigg M, Rüschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP.

Virchows Arch. 2013 Nov;463(5):623-31. doi: 10.1007/s00428-013-1492-3. Epub 2013 Oct 2.

PMID:
24085553
11.

Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.

Korphaisarn K, Pongpaibul A, Limwongse C, Roothumnong E, Klaisuban W, Nimmannit A, Jinawath A, Akewanlop C.

World J Gastroenterol. 2015 Jan 21;21(3):926-34. doi: 10.3748/wjg.v21.i3.926.

12.

Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.

Seppälä TT, Böhm JP, Friman M, Lahtinen L, Väyrynen VM, Liipo TK, Ristimäki AP, Kairaluoma MV, Kellokumpu IH, Kuopio TH, Mecklin JP.

Br J Cancer. 2015 Jun 9;112(12):1966-75. doi: 10.1038/bjc.2015.160. Epub 2015 May 14.

13.
14.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
15.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

16.

BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.

Chen J, Guo F, Shi X, Zhang L, Zhang A, Jin H, He Y.

BMC Cancer. 2014 Nov 3;14:802. doi: 10.1186/1471-2407-14-802.

17.

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?

Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, Carneiro F, Oliveira C, Seruca R.

BMC Cancer. 2008 Sep 9;8:255. doi: 10.1186/1471-2407-8-255.

18.

[KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese].

Zhu XL, Cai X, Zhang L, Yang F, Sheng WQ, Lu YM, Du X, Zhou XY.

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):584-9. doi: 10.3760/cma.j.issn.0529-5807.2012.09.003. Chinese.

PMID:
23157824
19.

Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.

Loughrey MB, Waring PM, Tan A, Trivett M, Kovalenko S, Beshay V, Young MA, McArthur G, Boussioutas A, Dobrovic A.

Fam Cancer. 2007;6(3):301-10. Epub 2007 Apr 24.

PMID:
17453358
20.

The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer.

Mancini I, Santucci C, Sestini R, Simi L, Pratesi N, Cianchi F, Valanzano R, Pinzani P, Orlando C.

J Mol Diagn. 2010 Sep;12(5):705-11. doi: 10.2353/jmoldx.2010.100018. Epub 2010 Jul 8.

Supplemental Content

Support Center